Loading
A phase 1 trial of Relcobatinib run by Enliven Therapeutics, now recruiting.
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia is a phase 1 interventional study registered as NCT05304377 by Enliven Therapeutics, with 250 participants planned, started 2022-05-22. Conditions recorded: Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive and Cml. Interventions recorded: ELVN-001.
Shares Relcobatinib, Enliven Therapeutics, Chronic myeloid leukaemia (CML), Acute myeloid leukaemia and the tag pipeline.
Shares Relcobatinib, Enliven Therapeutics, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Acute myeloid leukaemia and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/